key: cord-0802304-kln7f26y
authors: Byrnes, Sean; Bisen, Maneesh; Syed, Baseer; Huda, Syed; Siddique, Zaid; Sampat, Parth; Russo, Ronald; Oueida, Zaher; Johri, Geetanjali; Dargon, Ian
title: COVID‐19 encephalopathy masquerading as substance withdrawal
date: 2020-06-04
journal: J Med Virol
DOI: 10.1002/jmv.26065
sha: 6db2c5b121fa102186155a547b81b0e108fa5884
doc_id: 802304
cord_uid: kln7f26y

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), first identified in December 2019 in Wuhan, China, is the virus responsible for the current pandemic known as COVID-19. We report the case of a patient with past medical history of substance abuse who presented with suspected drug overdose. He was agitated and altered in the emergency room and he was treated with benzodiazepines for his agitation. He was admitted for substance withdrawal, however his encephalopathy did not improve and he developed choreiform movements. Metabolic, infectious, and rheumatologic workup was negative until he subsequently tested positive for COVID-19. An MRI was performed which showed multiple focal enhancing lesions primarily affecting the bilateral medial putamen and left cerebellum along with subcortical lesions suggesting COVID-19 encephalopathy. He was given glucocorticoids and his mentation and choreiform movements improved. While neurologic presentations are increasingly becoming more common, encephalopathy with choreiform movements appears to be a rare manifestation of SARS-CoV-2, and may be due to direct viral invasion or, more likely, autoimmune mediated toxicity precipitated by the initial viral infection This article is protected by copyright. All rights reserved.

To the Editor,

The most common presenting symptoms of COVID-19 include fever and cough, with neurologic complications becoming more widely recognized as presenting symptoms. 1 We report the case of a patient who presented with suspected drug overdose and was diagnosed with COVID-19 induced encephalopathy manifesting as choreiform movements. Choreiform movements appear to be a rare manifestation of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and may be due to direct viral central nervous system (CNS) invasion or, more likely, autoimmune-mediated toxicity precipitated by the initial viral infection.

A 36 years old otherwise healthy homeless male with known polysubstance abuse presented on 3/24/2020 for suspected drug overdose. On presentation, his vitals were normal except oxygen saturation was 99% on two liters per minute of oxygen, which he was weaned off of. Physical exam was limited because he received intramuscular midazolam before arrival. On examination, the patient was obtunded, with slurred speech and pinpoint pupils. Urine drug screen was positive for cocaine, opiates, and benzodiazepines, while blood alcohol level was undetectable. Laboratory studies showed a normal white blood cell count, decreased lymphocytes, mildly increased C-reactive protein, and erythrocyte sedimentation rate. A noncontrast computed tomography scan of the head was done which showed no acute infarct or intracranial hemorrhage. He began to regain consciousness in the emergency room but due to agitation was given further sedatives. He continued to have intermittent episodes of agitation for which he was given IV diazepam for presumed withdrawal symptoms. He was noted to have intermittent rapid, irregular, and nonpurposeful movements of the bilateral upper extremities for which a cause was not immediately identified. On day two he became febrile to 39.4°C, raising concern for an underlying infectious process.

Chest X-ray (CXR) did not show any active disease. Over concern for bacterial meningitis, he was then started on vancomycin and ceftriaxone. He continued to spike fevers and remained encephalopathic with choreiform movements, becoming increasingly hypoxic. Repeat Swab obtained on day 25 was negative, however, repeat swab the following day was positive. False negatives have been reported, attributed to operator error, differential viral shedding, or the sensitivity and specificity of the test itself. 2, 3 Due to this, the negative test on day 25 is believed to be a false negative. all of the previous differentials had either been ruled out, or were considered to be much less likely. Myelin basic protein, a sign of active myelin breakdown in the CSF, is commonly elevated in ADEM, as it is in our patient. Treatment is not well defined, with some patients responding to IVIG or glucocorticoids, as did our patient. 10 Coronaviruses like SARS-CoV-1 and MERS-CoV have been detected in the CSF of patients, suggesting direct neuroinvasive potential. 11 The pathologic mechanism of CNS invasion of COVID-19 may be similar to SARS-CoV-1, MERS-CoV, and various other respiratory viruses, but still requires further investigation. 12 Angiotensin-converting enzyme 2 (ACE2) has been recognized as a functional receptor for COVID-19, and ACE2 receptors have been found in various human organs including the nervous system, which may provide a direct route for viral entry after destruction of the blood-brain barrier. 13, 14 It remains unclear if pre-existing neurological conditions can predispose patients to CNS manifestations as demonstrated in a case where SARs-CoV-2 was isolated from brain tissue post-mortem in a patient with Parkinson's disease. 15 For the patient with COVID-19 and neurologic symptoms, brain imaging and LP are helpful in the diagnosis. Glucocorticoids should be considered on a case by case basis in patients with COVID-19 as they have been associated with worse clinical outcomes in certain patient populations. The long term effect of this complication remains unknown.

Neurologic complications in COVID-19 may be due to direct viral invasion or autoimmune-mediated toxicity precipitated by the initial viral infection. In patients with CNS involvement secondary to COVID-19, the prognosis remains unknown at this time but is believed to be poor, resulting in rapid clinical deterioration. COVID-19

can present with a wide spectrum of symptoms, and while encephalopathy is becoming an increasingly important presenting symptom, to our knowledge this is the first case of COVID-19 presenting as choreiform movements with encephalopathy. A patient F I G U R E 1 T1-weighted postcontrast MR on the brain in axial (A) and coronal (B) views. There is an enhancement of bilateral medial putamen (arrows). C, Axial T1-weighted postcontrast MR of the brain. There is a subtle faint enhancement of bilateral inferior temporal cortical and subcortical regions with involvement of the hippocampi, left greater than right. D, T1-weighted coronal postcontrast MR of the brain showing two enhancing lesions within the left cerebellum. MR, magnetic resonance

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: (Zhou et al. 2020) a retrospective cohort study. The Lancet

False Negatives and Reinfections: the Challenges of SARS-CoV-2 RT-PCR Testing

Recurrent recurrence of positive SARS-CoV-2 RNA in a COVID-19 patient

The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 2 pandemic infection: neurologists move to the frontlines

COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features

Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease

Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients

Acute disseminated encephalomyelitis: an update

Cerebral white matter: neuroanatomy, clinical neurology

Acute disseminated encephalomyelitis

Middle east respiratory syndrome

The emergence of a novel coronavirus (SARS-CoV-2). disease and their neuroinvasive propensity may affect in COVID-19 patients

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Central nervous system involvement by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2)